Intravenous Esketamine — Competitive Intelligence Brief

Intravenous Esketamine (Intravenous Esketamine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NMDA receptor antagonist. Area: Psychiatry / Mental Health.

marketed NMDA receptor antagonist NMDA receptor (N-methyl-D-aspartate receptor) Psychiatry / Mental Health Small molecule

Target snapshot

Intravenous Esketamine (Intravenous Esketamine) — Janssen Research & Development, LLC. Intravenous esketamine is an NMDA receptor antagonist that rapidly blocks glutamate signaling in the brain to produce fast-acting antidepressant effects.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Intravenous Esketamine TARGET	Intravenous Esketamine	Janssen Research & Development, LLC	marketed	NMDA receptor antagonist	NMDA receptor (N-methyl-D-aspartate receptor)
Intra-nasal ketamine	Intra-nasal ketamine	Lions Gate Hospital	marketed	NMDA receptor antagonist	NMDA receptor
Intraoperative infusion of esketamine	Intraoperative infusion of esketamine	Nanjing First Hospital, Nanjing Medical University	marketed	NMDA receptor antagonist	NMDA receptor
Rivastigmine, memantine	Rivastigmine, memantine	Novartis	marketed	Cholinesterase inhibitor and NMDA receptor antagonist combination	Acetylcholinesterase and NMDA receptor
Intranasal dexmedetomidine-esketamine	Intranasal dexmedetomidine-esketamine	Peking University First Hospital	marketed	Alpha-2 adrenergic agonist / NMDA receptor antagonist combination	Alpha-2 adrenergic receptors; NMDA receptor
Ketamine Injectable Product	Ketamine Injectable Product	Hackensack Meridian Health	marketed	NMDA receptor antagonist	NMDA receptor
Memantine Hydrochloride Tablets	Memantine Hydrochloride Tablets	University of Virginia	marketed	NMDA receptor antagonist	NMDA receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NMDA receptor antagonist class)

1. Turku University Hospital · 3 drugs in this class
2. H. Lundbeck A/S · 2 drugs in this class
3. Ciusss de L'Est de l'Île de Montréal · 2 drugs in this class
4. Shalvata Mental Health Center · 2 drugs in this class
5. New York State Psychiatric Institute · 2 drugs in this class
6. Auris Medical AG · 1 drug in this class
7. AstraZeneca · 1 drug in this class
8. Alameda Health System · 1 drug in this class
9. Centre Hospitalier Universitaire de Nice · 1 drug in this class
10. Asker & Baerum Hospital · 1 drug in this class